Prusogliptin (DBPR108) is an experimental DPP-4 inhibitor developed by CSPC Pharmaceutical Group to treat type 2 diabetes.
The compounds of every Wikipedia article carrying a Chembox or a Drugbox, refreshed daily, with the values their infoboxes give. The pages need JavaScript; the API does not.